Cargando…

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. SLC3A2 was assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: El Ansari, Rokaya, Craze, Madeleine L., Diez-Rodriguez, Maria, Nolan, Christopher C., Ellis, Ian O., Rakha, Emad A., Green, Andrew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931111/
https://www.ncbi.nlm.nih.gov/pubmed/29545595
http://dx.doi.org/10.1038/s41416-018-0038-5
_version_ 1783319597067272192
author El Ansari, Rokaya
Craze, Madeleine L.
Diez-Rodriguez, Maria
Nolan, Christopher C.
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
author_facet El Ansari, Rokaya
Craze, Madeleine L.
Diez-Rodriguez, Maria
Nolan, Christopher C.
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
author_sort El Ansari, Rokaya
collection PubMed
description Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. SLC3A2 was assessed at the genomic level, using METABRIC data (n = 1980), and at the proteomic level, using immunohistochemistry on tissue microarray (TMA) sections constructed from a large well-characterised primary BC cohort (n = 2500). SLC3A2 expression was correlated with clinicopathological parameters, molecular subtypes and patient outcome. SLC3A2 mRNA and protein expression were strongly correlated with higher tumour grade and poor Nottingham prognostic index (NPI). High expression of SLC3A2 was observed in triple-negative (TN), HER2+ and ER+ high-proliferation subtypes. SLC3A2 mRNA and protein expression were significantly associated with the expression of c-MYC in all BC subtypes (p < 0.001). High expression of SLC3A2 protein was associated with poor patient outcome (p < 0.001), but only in the ER+ high-proliferation (p = 0.01) and TN (p = 0.04) subtypes. In multivariate analysis SLC3A2 protein was an independent risk factor for shorter BC-specific survival (p < 0.001). SLC3A2 appears to play a role in the aggressive BC subtypes driven by MYC and could act as a potential prognostic marker. Functional assessment is necessary to reveal its potential therapeutic value in the different BC subtypes.
format Online
Article
Text
id pubmed-5931111
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59311112019-04-15 The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes El Ansari, Rokaya Craze, Madeleine L. Diez-Rodriguez, Maria Nolan, Christopher C. Ellis, Ian O. Rakha, Emad A. Green, Andrew R. Br J Cancer Article Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity and patient outcome. This study aimed to evaluate the biological and prognostic value of the membrane solute carrier, SLC3A2 in BC with emphasis on the intrinsic molecular subtypes. SLC3A2 was assessed at the genomic level, using METABRIC data (n = 1980), and at the proteomic level, using immunohistochemistry on tissue microarray (TMA) sections constructed from a large well-characterised primary BC cohort (n = 2500). SLC3A2 expression was correlated with clinicopathological parameters, molecular subtypes and patient outcome. SLC3A2 mRNA and protein expression were strongly correlated with higher tumour grade and poor Nottingham prognostic index (NPI). High expression of SLC3A2 was observed in triple-negative (TN), HER2+ and ER+ high-proliferation subtypes. SLC3A2 mRNA and protein expression were significantly associated with the expression of c-MYC in all BC subtypes (p < 0.001). High expression of SLC3A2 protein was associated with poor patient outcome (p < 0.001), but only in the ER+ high-proliferation (p = 0.01) and TN (p = 0.04) subtypes. In multivariate analysis SLC3A2 protein was an independent risk factor for shorter BC-specific survival (p < 0.001). SLC3A2 appears to play a role in the aggressive BC subtypes driven by MYC and could act as a potential prognostic marker. Functional assessment is necessary to reveal its potential therapeutic value in the different BC subtypes. Nature Publishing Group UK 2018-03-16 2018-04-17 /pmc/articles/PMC5931111/ /pubmed/29545595 http://dx.doi.org/10.1038/s41416-018-0038-5 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0).
spellingShingle Article
El Ansari, Rokaya
Craze, Madeleine L.
Diez-Rodriguez, Maria
Nolan, Christopher C.
Ellis, Ian O.
Rakha, Emad A.
Green, Andrew R.
The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
title The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
title_full The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
title_fullStr The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
title_full_unstemmed The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
title_short The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes
title_sort multifunctional solute carrier 3a2 (slc3a2) confers a poor prognosis in the highly proliferative breast cancer subtypes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931111/
https://www.ncbi.nlm.nih.gov/pubmed/29545595
http://dx.doi.org/10.1038/s41416-018-0038-5
work_keys_str_mv AT elansarirokaya themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT crazemadeleinel themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT diezrodriguezmaria themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT nolanchristopherc themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT ellisiano themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT rakhaemada themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT greenandrewr themultifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT elansarirokaya multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT crazemadeleinel multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT diezrodriguezmaria multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT nolanchristopherc multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT ellisiano multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT rakhaemada multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes
AT greenandrewr multifunctionalsolutecarrier3a2slc3a2confersapoorprognosisinthehighlyproliferativebreastcancersubtypes